Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02755181 · ClinicalTrials.gov registry record
fMRI in Impulsivity
A clinical trial of Borderline Personality Disorder and Impulse Control Disorders, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 48
- Enrollment target
- 1
- Study location
NCT02755181: Completed study of Borderline Personality Disorder and Impulse Control Disorders, sponsored by Boehringer Ingelheim.
NCT02755181 is a study of Borderline Personality Disorder and Impulse Control Disorders that has completed, run by Boehringer Ingelheim. The registered enrollment target is 48 participants, below the 105-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02755181, a study of Borderline Personality Disorder and Impulse Control Disorders, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to use resting-state and task based functional Magnetic Resonance Imaging (fMRI) as a tool to evaluate trait characteristics of impulsivity in subjects with borderline personality disorder.
Conditions Studied
Interventions
- BEHAVIORAL Experimental
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-07-22 |
| Est. Completion | 2018-05-30 |
What the finished NCT02755181 record still lists
NCT02755181 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 105-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Borderline Personality Disorder appearing as the primary indexed condition, and to 1 intervention - of which Experimental is the first listed.
NCT02755181 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT02755181 about?
NCT02755181 is a clinical study titled "fMRI in Impulsivity". This study aims to use resting-state and task based functional Magnetic Resonance Imaging (fMRI) as a tool to evaluate trait characteristics of impulsivity in subjects with borderline personality disorder.
What is the current status of trial NCT02755181?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2016-07-22. Estimated completion is 2018-05-30.
What conditions does trial NCT02755181 study?
This clinical trial studies the following conditions: Borderline Personality Disorder, Impulse Control Disorders.
What interventions are being tested in trial NCT02755181?
The interventions under investigation include: Experimental (BEHAVIORAL).
Who is sponsoring clinical trial NCT02755181?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02755181 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Personality Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02755181's enrollment target sits among peer trials
48 10th of 16 higher than 7 of 16 other Borderline Personality Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Borderline Personality Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MDMA in Borderline Personality Disorder
RECRUITING · Phase 2
-
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
RECRUITING · NA
-
Cognitive Reappraisal Training for Borderline Personality (BPD)
RECRUITING · NA
-
Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder
RECRUITING · Phase 2
-
Treatment of Borderline Personality Disorder With rTMS
RECRUITING · NA
-
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI